The pandemic is continuing to disrupt clinical trials in 2021, but the impact varies by therapeutic area, according to data analysis firm GlobalData.

The number of disrupted oncology, gastrointestinal, respiratory and immunology trials declined between April 2020 and February 2021, Global Data says. Oncology saw the largest decrease in the number of disrupted trials at 4.9 percent, followed by a 2.8 percent decline in the number of disrupted respiratory trials.

Meanwhile, the number of disrupted trials targeting musculoskeletal disorders, metabolic disorders, and cardiovascular and central nervous system (CNS) therapies increased between April 2020 and February 2021. CNS trials saw the largest increase at 4.1 percent, followed by metabolic disorders, which increased 3.3 percent.